Literature DB >> 6460761

An amphiphilic structure of the ninth component of human complement. Evidence from analysis of fragments produced by alpha-thrombin.

G Biesecker, C Gerard, T E Hugli.   

Abstract

Purified human C9 was treated separately with three proteolytic enzymes: trypsin, plasmin, and alpha-thrombin, and the digestion products were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Trypsin initially cleaved the Mr = 71,000 C9 to produce a Mr = 47,000 fragment plus numerous smaller fragments and prolonged digestion reduced the molecule to small polypeptides. Plasmin produced a Mr = 37,000 fragment which was stable to further digestion, plus fragments smaller than Mr = 10,000. Human alpha-thrombin cleaved C9 (7.8% carbohydrate) at a single internal site to produce a Mr = 37,000 fragment (11.3% carbohydrate) and a Mr = 34,000 fragment (3.9% carbohydrate). Statistical analysis of the amino acid compositions of the fragments and alkaline polyacrylamide gel electrophoresis showed that C9 is highly amphiphilic; the Mr = 34,000 fragment contains a majority of the acidic amino acids and migrates rapidly on alkaline gels; the Mr = 37,000 fragment is hydrophobic with a slow electrophoretic mobility. The two fragments remain noncovalently associated, but were separated by sodium dodecyl sulfate-hydroxylapatite chromatography. The NH2-terminal sequence analysis of native C9, of alpha-thrombin-cleaved C9, and for the isolated fragments showed that the acidic Mr = 34,000 fragment is the NH2-terminal C9a domain and the more hydrophobic Mr = 37,000 fragment is the carboxyl-terminal C9b domain. Hemolytic activity of C9 was unaffected by alpha-thrombin cleavage.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460761

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.

Authors:  J Tschopp; T E Mollnes
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

2.  Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9.

Authors:  R G DiScipio; M R Gehring; E R Podack; C C Kan; T E Hugli; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

Review 3.  The membrane attack complex.

Authors:  H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin.

Authors:  Jiusheng Deng; Daniel Gold; Philip T LoVerde; Zvi Fishelson
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity.

Authors:  K M Taylor; B P Morgan; A K Campbell
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

6.  The sequence and topology of human complement component C9.

Authors:  K K Stanley; H P Kocher; J P Luzio; P Jackson; J Tschopp
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

7.  Proteoform Profile Mapping of the Human Serum Complement Component C9 Revealing Unexpected New Features of N-, O-, and C-Glycosylation.

Authors:  Vojtech Franc; Yang Yang; Albert J R Heck
Journal:  Anal Chem       Date:  2017-03-07       Impact factor: 6.986

Review 8.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

Review 9.  Breaching the Bacterial Envelope: The Pivotal Role of Perforin-2 (MPEG1) Within Phagocytes.

Authors:  Leidy C Merselis; Zachary P Rivas; George P Munson
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.